Algeta schedules second quarter 2010 results presentation and webcast
(Thomson Reuters ONE) -
Oslo, Norway, 9 August 2010 - Algeta ASA (OSE: ALGETA), the focused oncology
company, will announce its second quarter 2010 results on Friday, 13 August
2010. A presentation to investors, analysts and the press will take place in
Oslo at 09:45 CET. Algeta's President and CEO Andrew Kay, CTO Thomas Ramdahl and
CFO Øystein Soug will present.
The presentation will also be webcast live and can be accessed from
www.algeta.com/webcast where questions can be submitted live during the
presentation.
The presentation will take place at 09:45 CET at:
Hotel Continental
Stortingsgaten 24/26
0117 Oslo
Norway.
The results report and the presentation will be made available on www.algeta.com
in the Investors section from 08:00 CET.
###
For further information, please contact
+47 2300 7990 / +47 4840 1360 (mob)
Andrew Kay, CEO
+47 2300 7990 / +47 9065 6525 (mob)
Øystein Soug, CFO
post(at)algeta.com
International media enquiries:
+44 207 638 9571
Mark Swallow/Helena Galilee/David Dible
mark.swallow(at)citigatedr.co.uk
Citigate Dewe Rogerson
US investor enquiries:
+1 646 378 2928
Jessica Lloyd
jlloyd(at)troutgroup.com
The Trout Group
About Algeta
Algeta is a focused oncology company developing novel targeted therapies for
patients with cancer based on its alpha-pharmaceutical platform.
Algeta's lead product Alpharadin (based on radium-223) is a first-in-class,
highly targeted alpha-pharmaceutical under clinical evaluation to improve
survival in patients with bone metastases from advanced cancer. Its localized
action helps preserve the surrounding healthy tissue thereby limiting
side-effects.
The development of bone metastases represents a serious development for cancer
patients as they are associated with a dramatic decline in patient health and
quality of life, ultimately leading to death. Bone metastases represent a major
unmet medical need, occurring in up to 90% of certain late-stage cancers, e.g.
prostate, breast and lung.
Alpharadin is being developed under a development and commercialization
agreement with Bayer Schering Pharma AG, a major pharmaceutical company, and is
in a global phase III clinical trial (ALSYMPCA) to treat bone metastases
resulting from castration-resistant (hormone-refractory) prostate cancer.
Alpharadin is also under investigation in phase II clinical trials as a
potential new treatment for bone metastases in endocrine resistant breast cancer
patients.
Algeta also aims to develop a future pipeline of tumor-targeting
alpha-pharmaceutical candidates based on the alpha particle emitter thorium-227,
through selective in-licensing and/or acquiring innovative technologies and
tumor-targeting molecules.
The Company is headquartered in Oslo, Norway, and was founded in 1997. Algeta
listed on the Oslo Stock Exchange in March 2007 (Ticker: ALGETA).
Alpharadin and Algeta are trademarks of Algeta ASA.
Forward-looking Statement
This news release contains forward-looking statements and forecasts based on
uncertainty, since they relate to events and depend on circumstances that will
occur in the future and which, by their nature, will have an impact on results
of operations and the financial condition of Algeta. There are a number of
factors that could cause actual results and developments to differ materially
from those expressed or implied by these forward-looking statements. Theses
factors include, among other things, risks associated with technological
development, the risk that research & development will not yield new products
that achieve commercial success, the impact of competition, the ability to close
viable and profitable business deals, the risk of non-approval of patents not
yet granted and difficulties of obtaining relevant governmental approvals for
new products.
###
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)
[HUG#1436510]
Press release:
http://hugin.info/134655/R/1436510/381554.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
All reproduction for further distribution is prohibited.
Source: Algeta ASA via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 09.08.2010 - 09:01 Uhr
Sprache: Deutsch
News-ID 39064
Anzahl Zeichen: 0
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 187 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Algeta schedules second quarter 2010 results presentation and webcast"
steht unter der journalistisch-redaktionellen Verantwortung von
Algeta ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
